169 related articles for article (PubMed ID: 27755240)
1. Role of biomarkers in monitoring antiblastic cardiotoxicity.
Novo G; Cadeddu C; Sucato V; Pagliaro P; Romano S; Tocchetti CG; Zito C; Longobardo L; Nodari S; Penco M
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e27-e34. PubMed ID: 27755240
[TBL] [Abstract][Full Text] [Related]
2. Role of biomarkers in monitoring antiblastic cardiotoxicity.
Novo G; Cadeddu C; Sucato V; Pagliaro P; Romano S; Tocchetti CG; Zito C; Longobardo L; Nodari S; Penco M
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S27-34. PubMed ID: 27183522
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicity due to Chemotherapy: the Role of Biomarkers.
Stevens PL; Lenihan DJ
Curr Cardiol Rep; 2015 Jul; 17(7):603. PubMed ID: 26026994
[TBL] [Abstract][Full Text] [Related]
4. Cardiac Biomarkers in Patients with Cancer: Considerations, Clinical Implications, and Future Avenues.
Bracun V; Aboumsallem JP; van der Meer P; de Boer RA
Curr Oncol Rep; 2020 Jun; 22(7):67. PubMed ID: 32514994
[TBL] [Abstract][Full Text] [Related]
5. Subclinical Cardiotoxicity: The Emerging Role of Myocardial Work and Other Imaging Techniques.
Di Lisi D; Manno G; Novo G
Curr Probl Cardiol; 2021 Jun; 46(6):100818. PubMed ID: 33756178
[TBL] [Abstract][Full Text] [Related]
6. Role of biomarkers in chemotherapy-induced cardiotoxicity.
Cardinale D; Sandri MT
Prog Cardiovasc Dis; 2010; 53(2):121-9. PubMed ID: 20728699
[TBL] [Abstract][Full Text] [Related]
7. Cancer Therapy-Related Cardiac Dysfunction: Unresolved Issues.
Marwick TH
Can J Cardiol; 2016 Jul; 32(7):842-6. PubMed ID: 27343742
[TBL] [Abstract][Full Text] [Related]
8. New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide.
van Boxtel W; Bulten BF; Mavinkurve-Groothuis AM; Bellersen L; Mandigers CM; Joosten LA; Kapusta L; de Geus-Oei LF; van Laarhoven HW
Biomarkers; 2015 Mar; 20(2):143-8. PubMed ID: 25980453
[TBL] [Abstract][Full Text] [Related]
9. Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy.
Virani SA; Dent S; Brezden-Masley C; Clarke B; Davis MK; Jassal DS; Johnson C; Lemieux J; Paterson I; Sebag IA; Simmons C; Sulpher J; Thain K; Thavendiranathan P; Wentzell JR; Wurtele N; Côté MA; Fine NM; Haddad H; Hayley BD; Hopkins S; Joy AA; Rayson D; Stadnick E; Straatman L
Can J Cardiol; 2016 Jul; 32(7):831-41. PubMed ID: 27343741
[TBL] [Abstract][Full Text] [Related]
10. Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.
Christenson ES; James T; Agrawal V; Park BH
Clin Biochem; 2015 Mar; 48(4-5):223-35. PubMed ID: 25445234
[TBL] [Abstract][Full Text] [Related]
11. Circulating Biomarkers for Cardiotoxicity Risk Prediction.
Gong FF; Cascino GJ; Murtagh G; Akhter N
Curr Treat Options Oncol; 2021 Apr; 22(6):46. PubMed ID: 33866434
[TBL] [Abstract][Full Text] [Related]
12. Biomarker Discovery in Cardio-Oncology.
Vohra A; Asnani A
Curr Cardiol Rep; 2018 May; 20(7):52. PubMed ID: 29802472
[TBL] [Abstract][Full Text] [Related]
13. The Role of Biomarkers in Cardio-Oncology.
Ananthan K; Lyon AR
J Cardiovasc Transl Res; 2020 Jun; 13(3):431-450. PubMed ID: 32642841
[TBL] [Abstract][Full Text] [Related]
14. The Role of Biomarkers to Evaluate Cardiotoxicity.
Upshaw JN
Curr Treat Options Oncol; 2020 Aug; 21(10):79. PubMed ID: 32767198
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular imaging in the diagnosis and monitoring of cardiotoxicity: cardiovascular magnetic resonance and nuclear cardiology.
Pepe A; Pizzino F; Gargiulo P; Perrone-Filardi P; Cadeddu C; Mele D; Monte I; Novo G; Zito C; Di Bella G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e45-e54. PubMed ID: 27755242
[TBL] [Abstract][Full Text] [Related]
16. Utilizing cardiac biomarkers to detect and prevent chemotherapy-induced cardiomyopathy.
Singh D; Thakur A; Tang WH
Curr Heart Fail Rep; 2015 Jun; 12(3):255-62. PubMed ID: 25869733
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers for monitoring chemotherapy-induced cardiotoxicity.
Cao L; Zhu W; Wagar EA; Meng QH
Crit Rev Clin Lab Sci; 2017 Mar; 54(2):87-101. PubMed ID: 28013560
[TBL] [Abstract][Full Text] [Related]
18. Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy.
Cardinale D; Biasillo G; Salvatici M; Sandri MT; Cipolla CM
Expert Rev Mol Diagn; 2017 Mar; 17(3):245-256. PubMed ID: 28092472
[TBL] [Abstract][Full Text] [Related]
19. Strategies for early detection of cardiotoxicities from anticancer therapy in adults: evolving imaging techniques and emerging serum biomarkers.
Akhter N; Murtagh G; Yancy C
Future Oncol; 2015; 11(14):2093-103. PubMed ID: 26198839
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of Doppler echocardiography, tissue Doppler imaging and biomarkers measurement for the detection of doxorubicin-induced cardiotoxicity in dogs: A pilot study.
Gallay-Lepoutre J; Bélanger MC; Nadeau ME
Res Vet Sci; 2016 Apr; 105():153-9. PubMed ID: 27033925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
